Skip to main content

Table 3 Most frequent (≥ 1.0%) treatment-emergent adverse events (randomized safety population) from the open-label PULSAR trial

From: Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)

  Number (%) of patients with adverse events
  Rosuvastatin 10 mg (n = 505) Atorvastatin 20 mg (n = 491)
Any adverse event 139 (27.5) 128 (26.1)
Myalgia 24 (4.8) 13 (2.6)
Urinary tract infection 13 (2.6) 16 (3.3)
Headache 8 (1.6) 7 (1.4)
Nausea 4 (0.8) 9 (1.8)
Bone pain 8 (1.6) 3 (0.6)
Muscle cramp 5 (1.0) 3 (0.6)
Peripheral edema 3 (0.6) 5 (1.0)